Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Clinical Pathology

• Publication date

  2005-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1309/KPXNVR7X4AMENBBEPMID 15899772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity

  2004cited by this paper
• CD22-directed monoclonal antibody therapy for lymphoma.

  2003cited by this paper
• Comparative analysis of light chain expression in germinal center cells and mantle cells of reactive lymphoid tissues. A four-color flow cytometric study.

  2003cited by this paper
• CD22 as a target of passive immunotherapy.

  2003cited by this paper
• Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation

  2002cited by this paper
• Two-color Flow Cytometry with a CD19 Gate for the Evaluation of Bone Marrow Involvement of B-cell Lymphoma

  2002cited by this paper
• The diagnostic value of kappa/lambda ratios determined by flow cytometric analysis of biopsy specimens in B-cell lymphoma.

  2002cited by this paper
• Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.

  2001cited by this paper
• Reference values for peripheral blood B-lymphocyte subpopulations: a basis for multiparametric immunophenotyping of abnormal lymphocytes.

  2001cited by this paper
• Differential expression of the B cell‐restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation

  2000cited by this paper
• Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia.

  1996cited by this paper
• Molecular mechanisms regulating CD19, CD20 and CD22 gene expression.

  1994cited by this paper
• Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia.

  1993cited by this paper
• The role of cell maturation in the generation of phenotypic heterogeneity in B-cell chronic lymphocytic leukaemia.

  1989cited by this paper
• Limitations of numerical ratios for defining monoclonality of immunoglobulin light chains in B-cell lymphomas.

  1985cited by this paper

• Insights into the transcriptional regulation of CD22 in B cell chronic lymphocytic leukemia

  2025cites this paper
• What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study

  2024cites this paper
• Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

  2023cites this paper
• Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors

  2022cites this paper
• CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.

  2022cites this paper
• Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy

  2022cites this paper
• Updates on CAR T‐cell therapy in B‐cell malignancies

  2019cites this paper
• Flow Cytometry of B-Cell Neoplasms.

  2017cites this paper
• Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.

  2017cites this paper
• Characterization of Molecular Correlates of the Chronic Humoral Immune Response: Clues towards Eliciting Broadly Neutralizing Antibodies against HIV

  2014cites this paper
• Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia

  2014cites this paper
• Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates

  2013cites this paper
• A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

  2013influential citation
• EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

  2012cites this paper
• Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

  2011cites this paper
• Design of Targeted Protein Toxins

  2011cites this paper
• Variables affecting the quantitation of CD22 in neoplastic B cells

  2011cites this paper
• Normal levels of peripheral CD19+CD5+ CLL‐like cells: Toward a defined threshold for CLL follow‐up—A GEIL‐GOELAMS study

  2011cites this paper
• In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

  2010cites this paper
• Lymphoid Leukaemias of Mature T, B and Natural Killer Cells

  2010cites this paper
• 2 – Principles of Immunophenotyping

  2008cites this paper
• Identification of genes associated with tumorigenesis of meibomian cell carcinoma by microarray analysis.

  2007cites this paper